Uncategorised - European Medical Journal

Sandoz’s Claire D’Abreu-Hayling on leading with love

Claire D’Abreu-Hayling, Chief Scientific Officer, Sandoz, shares how leading with love rather than ruling with an iron first is the best way to get results.

Spoonful of technology: May-June 2024

Explore the top tech stories that have shaped pharma in recent months as we explore implants to AI models, with a particular focus on antimicrobial resistance.

Women in Europe Are Receiving More Cycles of IVF: ESHRE 2024

Uptake of in vitro fertilisation and intrauterine insemination has increased among women in Europe, according to data presented at the ESHRE 40th annual meeting.

Socioeconomic Status Affects Fertility Treatment Outcomes: ESHRE 2024

New research presented at ESHRE highlights significant social disparities in achieving live births following assisted reproductive technology treatment.

Plants for Joints Trial: Breaking News from EULAR 2024

Results presented at EULAR 2024, show reductions in DAS28 scores among rheumatoid arthritis patients following a plant-based, whole-food diet, exercise, and stress management regime.

Phase III IMROZ Study of Isa-VRd in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Watch Thierry Facon highlight the Phase III IMROZ study: a global, randomised, Phase III, open-label study evaluating the efficacy and…

EASL 2024 Interview: Sven Francque

During my studies, I was most fascinated by the mechanisms behind diseases. That was what always triggered my interest, as well as trying…

EULAR 2024 Interview: Jette Primdahl

I started my career as a nurse, working for many years in cardiology, a speciality that I really liked. After further education, and…

Spotlight: June 2024

Discover June’s top pharma news in our monthly round-up. From the latest market predictions to new vaccine development initiatives, there’s plenty to discover.

GLP-1 treatments may lower cancer risk in type 2 diabetes patients

A new study finds that patients with type 2 diabetes taking GLP-1 treatments have a reduced chance of developing obesity-related cancers.